期刊
BLOOD
卷 117, 期 3, 页码 902-914出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-01-262691
关键词
-
类别
资金
- Associazione Genitori contro le Leucemie e Tumori Infantili Noi perVoi
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Citta della Speranza
- Ente Cassa di Risparmio di Firenze
- Universita di Firenze
- University of Milano Bicocca (Fondi di Ateneo per la Ricerca)
- Istituto Toscano Tumori
- PRIN
Bone marrow mesenchymal cells (MSCs) can protect leukemic cells from chemotherapy, thus increasing their survival rate. We studied the potential molecular mechanisms underlying this effect in acute lymphoblastic leukemia (ALL) cells. Coculture of ALL cells with MSCs induced on the lymphoblast plasma membrane the expression of a signaling complex formed by hERG1 (human ether-a-go-go-related gene 1) channels, the beta(1)-integrin subunit, and the chemokine receptor CXC chemokine receptor-4. The assembly of such a protein complex activated both the extracellular signal-related kinase 1/2 (ERK1/2) and the phosphoinositide 3-kinase (PI3K)/Akt prosurvival signaling pathways. At the same time, ALL cells became markedly resistant to chemotherapy-induced apoptosis. hERG1 channel function appeared to be important for both the initiation of prosurvival signals and the development of drug resistance, because specific channel blockers decreased the protective effect of MSCs. NOD/SCID mice engrafted with ALL cells and treated with channel blockers showed reduced leukemic infiltration and had higher survival rates. Moreover, hERG1 blockade enhanced the therapeutic effect produced by corticosteroids. Our findings provide a rationale for clinical testing of hERG1 blockers in the context of antileukemic therapy for patients with ALL. (Blood.2011;117(3):902-914)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据